IBDEI0SJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13383,0)
 ;;=D62.^^53^593^18
 ;;^UTILITY(U,$J,358.3,13383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13383,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,13383,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,13383,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,13384,0)
 ;;=C92.41^^53^593^19
 ;;^UTILITY(U,$J,358.3,13384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13384,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,13384,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,13384,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,13385,0)
 ;;=C92.40^^53^593^20
 ;;^UTILITY(U,$J,358.3,13385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13385,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,13385,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,13385,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,13386,0)
 ;;=D56.0^^53^593^21
 ;;^UTILITY(U,$J,358.3,13386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13386,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,13386,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,13386,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,13387,0)
 ;;=D63.1^^53^593^23
 ;;^UTILITY(U,$J,358.3,13387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13387,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,13387,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,13387,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,13388,0)
 ;;=D63.0^^53^593^24
 ;;^UTILITY(U,$J,358.3,13388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13388,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,13388,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,13388,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,13389,0)
 ;;=D63.8^^53^593^22
 ;;^UTILITY(U,$J,358.3,13389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13389,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,13389,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,13389,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,13390,0)
 ;;=C22.3^^53^593^26
 ;;^UTILITY(U,$J,358.3,13390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13390,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,13390,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,13390,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,13391,0)
 ;;=D61.9^^53^593^27
 ;;^UTILITY(U,$J,358.3,13391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13391,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,13391,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,13391,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,13392,0)
 ;;=D56.1^^53^593^29
 ;;^UTILITY(U,$J,358.3,13392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13392,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,13392,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,13392,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,13393,0)
 ;;=C83.79^^53^593^31
 ;;^UTILITY(U,$J,358.3,13393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13393,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13393,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,13393,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,13394,0)
 ;;=C83.70^^53^593^32
 ;;^UTILITY(U,$J,358.3,13394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13394,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,13394,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,13394,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,13395,0)
 ;;=D09.0^^53^593^39
 ;;^UTILITY(U,$J,358.3,13395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13395,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,13395,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,13395,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,13396,0)
 ;;=D06.9^^53^593^40
